ESLAW
Estrella Immunopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.08
+3.33%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +18.9%
- EBIT
- +18.9%
- EPS
- +25.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +34.7%
- EPS
- -52.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -47.7%
- EBIT
- -47.7%
- Net income
- -47.6%
- EPS
- -45.8%
- Free cash flow
- +42.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026